The National Institute on Aging and Alzheimer's Association (NIA-AA) has proposed a research framework for using A/T/N biomarkers of β amyloid, tau, and neurodegeneration biomarkers to define Alzheimer's disease. The gene discussed is MAPT; the disease is Alzheimer disease.